277 related articles for article (PubMed ID: 28566949)
1. The potential role of neuroinflammation and transcription factors in Parkinson disease.
Tiwari PC; Pal R
Dialogues Clin Neurosci; 2017 Mar; 19(1):71-80. PubMed ID: 28566949
[TBL] [Abstract][Full Text] [Related]
2. Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease.
Kaur K; Gill JS; Bansal PK; Deshmukh R
J Neurol Sci; 2017 Oct; 381():308-314. PubMed ID: 28991704
[TBL] [Abstract][Full Text] [Related]
3. Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson's disease.
Pal R; Tiwari PC; Nath R; Pant KK
Neurol Res; 2016 Dec; 38(12):1111-1122. PubMed ID: 27808010
[TBL] [Abstract][Full Text] [Related]
4. Role of p38 and inducible nitric oxide synthase in the in vivo dopaminergic cells' degeneration induced by inflammatory processes after lipopolysaccharide injection.
Ruano D; Revilla E; Gavilán MP; Vizuete ML; Pintado C; Vitorica J; Castaño A
Neuroscience; 2006 Jul; 140(4):1157-68. PubMed ID: 16713109
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory response in Parkinson's disease (Review).
Yan J; Fu Q; Cheng L; Zhai M; Wu W; Huang L; Du G
Mol Med Rep; 2014 Nov; 10(5):2223-33. PubMed ID: 25215472
[TBL] [Abstract][Full Text] [Related]
6. Neuroinflammation in Parkinson's disease.
Lee JK; Tran T; Tansey MG
J Neuroimmune Pharmacol; 2009 Dec; 4(4):419-29. PubMed ID: 19821032
[TBL] [Abstract][Full Text] [Related]
7. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
Zhang QS; Heng Y; Yuan YH; Chen NH
Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
[TBL] [Abstract][Full Text] [Related]
8. Vanillin Protects Dopaminergic Neurons against Inflammation-Mediated Cell Death by Inhibiting ERK1/2, P38 and the NF-κB Signaling Pathway.
Yan X; Liu DF; Zhang XY; Liu D; Xu SY; Chen GX; Huang BX; Ren WZ; Wang W; Fu SP; Liu JX
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208679
[TBL] [Abstract][Full Text] [Related]
9. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Hirsch EC; Hunot S
Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921
[TBL] [Abstract][Full Text] [Related]
10. Neuroinflammatory processes in Parkinson's disease.
Hirsch EC; Hunot S; Hartmann A
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S9-S15. PubMed ID: 15885630
[TBL] [Abstract][Full Text] [Related]
11. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease.
Panaro MA; Cianciulli A
Curr Pharm Des; 2012; 18(2):200-8. PubMed ID: 22229581
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease.
Tripathy D; Chakraborty J; Mohanakumar KP
Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946
[TBL] [Abstract][Full Text] [Related]
13. β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease.
Ojha S; Javed H; Azimullah S; Haque ME
Mol Cell Biochem; 2016 Jul; 418(1-2):59-70. PubMed ID: 27316720
[TBL] [Abstract][Full Text] [Related]
14. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.
Collins LM; Toulouse A; Connor TJ; Nolan YM
Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232
[TBL] [Abstract][Full Text] [Related]
15. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?
Tansey MG; Frank-Cannon TC; McCoy MK; Lee JK; Martinez TN; McAlpine FE; Ruhn KA; Tran TA
Front Biosci; 2008 Jan; 13():709-17. PubMed ID: 17981581
[TBL] [Abstract][Full Text] [Related]
16. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
17. Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.
Thome AD; Standaert DG; Harms AS
PLoS One; 2015; 10(10):e0140566. PubMed ID: 26469270
[TBL] [Abstract][Full Text] [Related]
18. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
19. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.
Qian L; Flood PM; Hong JS
J Neural Transm (Vienna); 2010 Aug; 117(8):971-9. PubMed ID: 20571837
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.
Tai W; Ye X; Bao X; Zhao B; Wang X; Zhang D
Neuropharmacology; 2013 Dec; 75():201-12. PubMed ID: 23916477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
